Pharmacogenomics Testing for Optimal Medication Management in Allogeneic Blood and Marrow Post-transplant Patients


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 17-001202
    Sponsor Protocol Number: 17-001202

About this study

The purpose of this study is to assess the clinical utility of pharmacogenomics testing in the management of allogeneic BMT patients; assess the role of pharmacogenomics testing in medication selection and dose in the first 100 days post-transplant.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Adult blood or marrow transplant patients with a hematologic disorder undergoing an allogeneic bone marrow, cord blood or stem cell transplant at Mayo Clinic Rochester

Exclusion Criteria:

  • Patients unwilling to give research authorization 
  • Who are not English speaking.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mary Thoma, P.A.-C.

Open for enrollment

Contact information:

Mary Thoma P.A.-C.



Mayo Clinic Footer